XB100
The World's Top 100 Private Deep Tech Companies
The XB100 is the definitive ranking of the world's top 100 private deep technology companies, brought to you by XPRIZE and Bessemer Venture Partners.
Report
State of Deep Tech
In this exclusive report, we break down the nine deep tech sectors represented in the XB100, from agriculture to quantum and space. Navigate here to read the benchmarks and trends that emerged from our research and our perspective on the challenges facing deep tech founders in the coming years.

Featured company interviews
Judges
Anousheh Ansari
Astronaut and CEO of XPRIZE
Emily Calandrelli
Science Communicator, Author, and Emmy-nominated TV Host
Lori Garver
Co-founder of the Brooke Owens Fellowship and former Deputy Administrator at NASA
Ray Johnson
CEO of Technology Innovation Institute and former CTO of Lockheed Martin
Stacy Kauk
Sustainability Expert
Ray Kurzweil
Author, Inventor, and Futurist
Tina Seelig
Executive Director of Knight-Hennessy Scholars at Stanford University
Explore More
Deep tech reading
Methodology
The XB100 is delineated into 9 categories: Agriculture, Artificial intelligence (AI), Aviation, Climate, Mobility, Next-gen biotech, Quantum, Robotics, and Space. We evaluated these businesses based on the following four criteria.
01. Impact on humanity
Seven judges evaluated each category's impact on humanity: Anousheh Ansari, Emily Calandrelli, Lori Garver, Ray Johnson, Stacy Kauk, Ray Kurzweil, and Tina Seelig.
02. Valuation
We obtained the last known valuation of the company based on third-party data providers, industry valuation methods, and additional factors.
03. Scientific difficulty
To assess the difficulty of a company's scientific research, we relied on two proxies: (a) the number of PhDs at the company based on third-party data providers, and (b) the number of patents granted to the company according to geographical patent databases.
04. Commercial traction
We scored commercial traction using the Technology Readiness Level framework standardized by NASA. In the case of biotech companies, we examined whether a company is going through clinical trials.